October 26, 2018 — Sun Nuclear Corp. announced the 100th shipment of its new SRS MapCheck for stereotactic radiosurgery (SRS). The milestone device will be used at a new Kaiser Permanente facility in California to help with commissioning of their stereotactic program, including end-to-end testing and dosimetric validations.
Released in May 2018, the SRS MapCheck has generated significant clinical interest from radiation therapy clinics worldwide, according to Sun Nuclear. With the recent release of its latest integrated software, SNC Patient v8.1, the SRS MapCheck provides absolute dose.
The SRS MapCheck is a stereotactic patient quality assurance (QA) tool that replaces film for patient-specific stereotactic QA. It was designed to insert into Sun Nuclear’s StereoPhan phantom for stereotactic commissioning and end-to-end testing. Together, these tools expedite the workflow for time-sensitive patient QA.
“The SRS MapCHECK shows very good agreement with film dosimetry for field sizes ranging from 7.0 cm to 0.5 cm,” noted Brett Miller, MS, DABR, University of Tennessee Medical Center, an early adopter of SRS MapCheck. “It proves to be an effective, time-saving substitute for film and point dose measurements.”
SNC Patient software compares the dose distribution of the treatment plan file imported from a treatment planning system (TPS) to the actual measured values. The release of v8.1 adds the Absolute Dose feature. With this release, users can query various points from the dose distribution, including absolute dose from the measured and planned dose data, absolute and relative dose difference between measured and planned dose data, and location relative to isocenter. Measurements use standard radiotherapy dose comparison metrics: gamma analysis, dose difference analysis and supports sub-millimeter distance criterion.
SRS MapCheck was on display at the 2018 American Society for Radiation Oncology (ASTRO) annual meeting, Oct. 21-24 in San Antonio, Texas.
For more information: www.sunnuclear.com
